Percheron Therapeutics Limited has released a press release.
Prospectus
Filed with ASX ·
On 6ix: 6ix.com/news/prospectus-161
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Story so far
Earlier from Percheron Therapeutics
- Bonus Option Offer
- Long COVID-19 strategic collaboration with US Experts
- Dosing commenced in MCRI collaboration animal study
- Quarterly Report and Appendix 4C
- Entitlement Offer Results
Later from Percheron Therapeutics
- New Indication for ATL1102 Limb Girdle Muscular Dystrophy R2
- ATL1102 DMD Clinical Trial Application Submitted in Europe
- Voluntary Suspension
- Long Covid-19 Collaboration Outcomes Presentation
- Reinstatement to Official Quotation
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics